Vistin Pharma ASA reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was NOK 91.71 million compared to NOK 62.85 million a year ago. Net loss was NOK 6.7 million compared to net income of NOK 0.947 million a year ago. Basic loss per share from continuing operations was NOK 0.15 compared to basic earnings per share from continuing operations of NOK 0.02 a year ago. Diluted loss per share from continuing operations was NOK 0.15 compared to diluted earnings per share from continuing operations of NOK 0.02 a year ago.
For the nine months, sales was NOK 193.92 million compared to NOK 200.5 million a year ago. Net loss was NOK 21.61 million compared to net income of NOK 17.8 million a year ago. Basic loss per share from continuing operations was NOK 0.49 compared to basic earnings per share from continuing operations of NOK 0.4 a year ago. Diluted loss per share from continuing operations was NOK 0.49 compared to diluted earnings per share from continuing operations of NOK 0.4 a year ago.